Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: The USA Food and Drug Administration (FDA) approved VENTANA anti-ALK (D5F3) CDx assay can more accurately identify a new ALK clone, 5A4 than any other commonly used immunohistochemistry (IHC) assay, for the selection of ALK rearranged lung adenocarcinoma patients eligible to receive Crizotinib therapy. However, Indian data on efficacy of Crizotinib in IHC positive non-small-cell lung cancer patients is lacking.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
